MiNK Therapeutics (NASDAQ:INKT) unveiled new translational data at the Keystone Symposia on Wednesday, providing the first direct evidence in humans that a specific immune cell deficiency may be a primary driver of the scarring that defines idiopathic pulmonary fibrosis (IPF).
The data, presented by Dr. Terese Hammond, Head of Pulmonary and Inflammatory Diseases at MiNK, showed a "significant and profound" depletion of invariant natural killer T (iNKT) cells in the lung-associated lymph nodes of patients with end-stage IPF.
The findings suggest that the loss of these "master regulators" of the immune system prevents the body from halting the chronic inflammation that leads to irreversible lung scarring.
The discovery effectively expands MiNK’s reach beyond oncology and into the $4 billion IPF market, where current treatments can only slow—rather than stop or reverse—the disease's progression.
Management noted that the findings provide a clear mechanistic rationale for using the company's lead candidate, agenT-797, an off-the-shelf allogeneic iNKT cell therapy, to replenish these cells and potentially restore immune balance in fibrotic lungs.
MiNK, a clinical-stage subsidiary of Agenus (NASDAQ:AGEN), is already testing agenT-797 in solid tumors and graft-versus-host disease (GvHD).
The company ended 2025 with approximately $14.3 million in cash, and analysts have noted that the expansion into pulmonary fibrosis significantly increases the company's potential as a partnership candidate for larger pharmaceutical firms seeking a foothold in regenerative lung medicine.